Evaluation of 90Y-DTPA and 90Y-DOTA for potential application in intra-vascular radionuclide therapy

90Y-1,4,7,10-tetraazacyclododecane tetraacetic acid (90Y-DOTA) and 90Y-diethylene triamine pentaacetic acid (90Y-DTPA) complexes were studied for possible use in intra-vascular radionuclide therapy (IVRNT). 90Y was obtained from a 90Sr–90Y generator based on supported liquid membrane technique. The 90Y-DOTA and 90Y-DTPA complexes were prepared under optimised conditions. Bio-distribution of the complexes in Swiss mice showed that nearly 90% of 90Y complexes of both the ligands were excreted via urine within 1 h post-injection with negligible localisation in vital organs. Probenecid inhibition studies showed that both complexes are excreted by glomerular filtration. The predominant and quick excretion of 90Y-DOTA and 90Y-DTPA through the kidneys suggest that both these complexes could be explored for use in IVRNT.